News

India Launches First-of-its-Kind Medical Research Centre to Advance Clinical Trials

With the Medical Research Centre approaching operational status, India is set to enhance its capacity for clinical research and public health preparedness. The facility is expected to contribute significantly to biomedical innovation and the country’s ability to respond to future disease outbreaks.

• By Pooja Sah
• New Delhi
• Jul 16, 2025

News

In a significant step for India’s scientific and healthcare landscape, Union Science & Technology Minister Dr Jitendra Singh has unveiled the country’s first-of-its-kind Medical Research Centre (MRC) at the Translational Health Science & Technology Institute (THSTI) in Faridabad. The ambitious facility aims to strengthen India’s capacity to conduct advanced clinical research, including studies on infections, new diagnostics, treatments, and vaccines.

Centre Equipped for Infection Studies

Designed to tackle pressing public health challenges, the MRC includes specialised wings focused on enteric and respiratory infections. It will also host facilities for diagnostic research and therapeutic trials.

One of the centre’s key highlights is a Controlled Human Infection Facility, described as “one of the few in the region,” which will allow researchers to safely and ethically study disease mechanisms and test new interventions directly in human volunteers.

Such capabilities could help India accelerate its research on emerging infectious diseases, a lesson underscored by the COVID-19 pandemic.

Facility Nears Operational Stage

During his visit on THSTI’s 16th Foundation Day on July 15, Dr Singh inspected the newly constructed building and reviewed progress on equipment installation and operational readiness.

With much of the infrastructure complete, the institute is now gearing up to launch full-scale research and clinical activities in the coming months.

Role in Pandemic Preparedness

Speaking at the event, Dr Singh praised THSTI for translating research into practical solutions, remarking:

“Each year, I am more impressed by the strides you make in translational health science,” he said, adding that THSTI “exemplifies how research institutions can bridge the gap between scientific discovery and real-world application.”

He also noted THSTI’s important contributions during the COVID-19 crisis, including early work on DNA vaccine trials and immune response studies that informed public health strategies.

Recognised on Global Stage

India’s growing research profile is reflected in recent achievements highlighted by Dr Singh.

These include the development of monoclonal antibodies targeting the deadly Nipah virus—an effort rare among low- and middle-income countries. THSTI has also been chosen by CEPI (the Coalition for Epidemic Preparedness Innovations) as Asia’s first Pre-clinical Network Laboratory, and only the ninth worldwide, signifying international recognition of its expertise.

Additionally, the institute has expanded its animal research facilities and established Ge-HuMiC, a unique collection of genetically defined human-associated microbes, which could open new avenues for studying human health and disease.

Industry Partnerships on the Rise

Beyond its scientific work, THSTI is cultivating strong ties with industry partners.

At the SYNCH-N 2025 event held a day before the inauguration, the institute signed 18 Letters of Intent and agreements with various stakeholders.

“Your work is directly contributing to a healthier, more resilient India,” Dr Singh told researchers, pointing to the growing emphasis on collaborations that bring discoveries from labs to patients faster.

Eye on Future Research

Next door to the MRC, a new Translational Research Facility (TRF) is also in the works.

The TRF will support development efforts for vaccines, monoclonal antibodies, diagnostics, and other biotherapeutics. It’s expected to host several Centres of Excellence that will draw on both academic expertise and industry partnerships, creating a robust ecosystem for medical innovation.

A Strategic Leap for India

India’s push to enhance its clinical research infrastructure reflects a broader ambition to become a global player in biomedical science. Facilities like the MRC are poised to help the country:

• Conduct early-phase human trials domestically, cutting reliance on overseas labs.

• Respond quickly to emerging infectious diseases.

• Accelerate the translation of scientific discoveries into treatments and preventive tools.

Industry experts have noted that India’s diverse patient population and cost advantages are positioning it as an attractive hub for global clinical trials.

With the Medical Research Centre approaching operational status, India is set to enhance its capacity for clinical research and public health preparedness. The facility is expected to contribute significantly to biomedical innovation and the country’s ability to respond to future disease outbreaks. Researchers and policymakers are monitoring its progress as it becomes integrated into India’s health research infrastructure.